Oryzon leverages epigenetics to develop small-molecule therapies, with a strong focus on personalized medicine in CNS disorders and oncology. Its advanced clinical portfolio centers on two LSD1 inhibitors: vafidemstat (CNS) and iadademstat (oncology), both in multiple Phase II trials. Vafidemstat is in Phase IIb studies including PORTICO (borderline personality disorder) and EVOLUTION (schizophrenia) and Oryzon is preparing additional trials (e.g., Kabuki Syndrome and other neurodevelopmental indications). Iadademstat has been evaluated across several trials (including FRIDA, ALICE and CLEPSIDRA), has been dosed in over 100 cancer patients, and benefits from collaborations such as a CRADA with the U.S. NCI and orphan designations for SCLC and AML. The company’s team is based in Barcelona, with presence in Boston and San Diego. The announced financing with Nice & Green is intended to strengthen the balance sheet and extend cash runway to support ongoing pivotal activities and partner discussions. Oryzon Genomics is a clinical-stage biopharmaceutical company founded in 2000 in Barcelona that develops therapies based on epigenetics for oncology and neurodegenerative diseases. Its lead programs are ORY-1001 for acute myeloid leukemia and ORY-2001 for cognitive decline and memory loss, with ORY-1001 entering Phase IIA enrollment and ORY-2001 expected to begin human trials in early 2016. Oryzon also advances earlier-stage epigenetic-targeted programs and operates a biomarker identification and validation platform; its LSD1 program is covered by 19 patent families. The company completed a $19 million private placement that issued 4.9 million new common shares at €3.39 per share and values the company at $110 million post-transaction. Proceeds will be used to advance ORY-1001 and ORY-2001 and to accelerate earlier-stage programs, complementing potential milestone payments from Roche tied to a strategic collaboration for ORY-1001 with possible value above $500 million. Oryzon opened U.S. operations in Cambridge, Massachusetts in 2014 and expects to list on the Madrid Stock Exchange before year-end with a potential future dual listing on NASDAQ.

Total raised

$54M

Funding rounds

2

Latest round

Convertible Note

Latest activity

Nov 2023